The HIV Drugs Market size is expected to reach USD 43.06 Bn by 2031 and was valued at USD 32.7 Bn in 2023, the CAGR growth rate for HIV drug market is expected 3.5% over the forecast period of 2024-2031.
For the treatment of HIV (Human Immunodeficiency Virus) infection, various medication classes are available. These medications support the management of the virus, reduce its development, and stop the onset of AIDS (Acquired Immunodeficiency Syndrome). Remember that the field of HIV research and treatment is continually changing, so there may have been advancements made since then. These are the primary categories of HIV medications: Nucleoside reverse transcriptase inhibitors (NRTIs): These medications prevent the virus from reproducing its genetic material by interfering with the reverse transcriptase enzyme. Zidovudine (AZT), lamivudine (3TC), and tenofovir disoproxil fumarate (TDF) are a few examples. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): NNRTIs work by interacting with a different location on the reverse transcriptase enzyme than NRTIs do. Efavirenz, nevirapine, and rilpivirine are a few examples. Protease Inhibitors (PIs): Protease inhibitors prevent the protease enzyme, which HIV needs to produce mature, contagious virus particles, from working. Ritonavir, atazanavir, and darunavir are a few examples. Inhibitors of Integrase Strand Transfer (INSTIs): INSTIs work by inhibiting the integrase enzyme, blocking the integration of viral DNA into the DNA of the host cell. Raletegravir, dolutegravir, and bictegravir are other examples. Fusion Inhibitors: By disrupting the fusion of the virus and the cell membrane, these medications stop HIV from entering the host cell. An illustration of a fusion inhibitor is enfuvirtide. Entry Inhibitors: By blocking the CCR5 receptor on CD4 cells' surface, these medications stop HIV from entering the cell. An example of an entrance inhibitor is maraviroc.
Get More Information on HIV Drugs Market - Request Sample Report
Geographical location, demographics, healthcare accessibility, preventative initiatives, and sociocultural variables can all play a role in the causes of the increase in HIV incidence. While I can offer some broad perspectives, it is crucial to keep in mind that there may be many different factors contributing to the rise in HIV incidence. The following are some proposed causes of the increase in HIV cases: There may be a dearth of knowledge regarding HIV, its methods of transmission, and protective measures in some areas. A lack of education may cause individuals to engage in risky behaviours that raise the possibility of HIV transmission. The stigma attached to HIV might deter people from getting tested, getting treatment, and disclosing their status. Fear of being marginalised and subjected to prejudice could.
Driver
Rise in the Scientific Research and Advances
The processes of HIV infection and replication have been better understood thanks to developments in virology, immunology, and molecular biology. Due to this understanding, therapeutic targets have been found and medications that can disrupt different phases of the viral lifecycle have been created.
Opportunity
Clinical Trials and Regulatory Approvals
To evaluate the efficacy and safety of possible HIV medications, thorough clinical trials are carried out. Drugs are approved for sale after regulatory agencies, including the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), analyse trial data.
Restrain
The high cost and the affordability factor.
Challenge
The availability of HIV testing and treatment services may be constrained by underdeveloped healthcare systems, inadequate medical facilities, and a lack of educated healthcare workers.
Impact of Recession
Governments and organisations may experience budgetary difficulties during a recession, which could result in the reduction of financing for healthcare initiatives, such as those aimed at HIV prevention, testing, and treatment. This might reduce the resources available to help those in need get HIV medications. Economic downturns have the potential to disrupt pharmaceutical supply chains, which could result in shortages or pauses in the availability of HIV medications. Particularly if medicine production or delivery is hampered, this may have an impact on both home and foreign markets. Recessions frequently lead to job losses and higher unemployment rates, as well as the loss of health insurance. People who lose their jobs could also stop having health insurance, making it more challenging for them to get and afford.
Infrastructure, supply chains, and healthcare systems can all be affected by armed conflict. Access to necessary pharmaceuticals, particularly HIV meds, may be restricted due to damage to hospitals, clinics, and pharmacies or closure of those facilities. Population Displacement: Conflict-related population displacement can result in the eviction of significant populations from their homes and communities. Accessing standard healthcare services, such as HIV testing and care, may become difficult as a result. Limited Access to Medicines: During conflicts, supply lines for medicines might be affected, resulting in shortages, and making it difficult to get and distribute necessary pharmaceuticals. This may affect how easily people can obtain HIV drugs on a regular basis. Shortages in the Healthcare Workforce: The conflict may have a direct impact on healthcare professionals, which could result in a lack of qualified employees. This may affect how healthcare is delivered.
By Drug Class
Integrase Inhibitors
Non- Nucleoside Reverse Transcriptase inhibitors (NRITs)
Combination HIV medicines
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
The major key players are ViiV Healthcare, Gilead Sciences, GlaxoSmithKline, Merck Sharp & Dohme Corp, Bristol -Myers Squibb Co, Janssen Pharmaceuticals, Boehringer Ingelheim International, Abbvie, Genentech, Mylan, Others.
Regional Analysis:
Due to advanced healthcare systems, access to HIV medications is generally good in nations like the United States and Canada. For some people, especially those without health insurance, affordability may be a problem. There are several different pharmacological classes for treating HIV, and novel therapies with increased efficacy and fewer adverse effects are frequently available. A variety of HIV medications are available because to the robust healthcare systems seen in many European nations. Due to some countries' universal healthcare coverage, affordability might not be as much of a concern. Various nations have different HIV prevalence rates, which has an impact on the demand for and supply of medications.
ViiV Healthcare- The European Medicines Agency gives the positive CHMP onionin to the company’s CABOTEGRAVIR which is used for the HIV prevention.
Gilead Sciences – The company present the new data from the HIV cure Research Program and Collaborations.
| Report Attributes | Details |
| Market Size in 2023 | US$ 32.7 Bn |
| Market Size by 2031 | US$ 43.06 Bn |
| CAGR | CAGR of 3.5 % From 2024 to 2031 |
| Base Year | 2023 |
| Forecast Period | 2024-2031 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Drug Class (Integrase Inhibitors, Non- Nucleoside Reverse Transcriptase inhibitors (NRITs), Combination HIV medicines, Others) • By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]). Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) |
| Company Profiles | ViiV Healthcare, Gilead Sciences, GlaxoSmithKline, Merck Sharp & Dohme Corp, Bristol -Myers Squibb Co, Janssen Pharmaceuticals, Boehringer Ingelheim International, Abbvie, Genentech, Mylan |
| Key Drivers | • Rise in the Scientific Research and Advances |
| Market Restraints | • The high cost and the affordability factor. |
Ans. The Compound Annual Growth rate for HIV Drugs Market over the forecast period is 3.5%.
Ans. USD 43.06 Billion is the projected HIV Drugs market size of market by 2031.
Ans. The major key players are ViiV Healthcare, Gilead Sciences, GlaxoSmithKline, Merck Sharp & Dohme Corp, Bristol -Myers Squibb Co, Janssen Pharmaceuticals, Boehringer Ingelheim International, Abbvie, Genentech, Mylan, Others.
Ans. North America is the fastest growing region of the HIV Drugs Market.
Ans. The key drivers are rise in the Scientific Research and Advances
TABLE OF CONTENT
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
4. Impact Analysis
4.1 Impact of the Russia-Ukraine War
4.2 Impact of Ongoing Recession
4.2.1 Introduction
4.2.2 Impact on major economies
4.2.2.1 US
4.2.2.2 Canada
4.2.2.3 Germany
4.2.2.4 France
4.2.2.5 United Kingdom
4.2.2.6 China
4.2.2.7 Japan
4.2.2.8 South Korea
4.2.2.9 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. HIV Drugs Market Segmentation, by Drug Class
8.1 Integrase Inhibitors
8.2 Non- Nucleoside Reverse Transcriptase inhibitors (NRITs)
8.3 Combination HIV medicines
8.4 Others
9. HIV Drugs Market Segmentation, by Distribution Channel
9.1 Hospital Pharmacies
9.2 Retail Pharmacies
9.3 Online Pharmacies
9.4 Others
10. Regional Analysis
10.1 Introduction
10.2 North America
10.2.1 North America HIV Drugs Market by Country
10.2.2 North America HIV Drugs Market by Drug class
10.2.3 North America HIV Drugs Market by Distribution Channel
10.2.4 USA
10.2.4.1 USA HIV Drugs Market by Drug class
10.2.4.2 USA HIV Drugs Market by Distribution Channel
10.2.5 Canada
10.2.5.1 Canada HIV Drugs Market by Drug class
10.2.5.2 Canada HIV Drugs Market by Distribution Channel
10.2.6 Mexico
10.2.6.1 Mexico HIV Drugs Market by Raw Technology
10.2.6.2 Mexico HIV Drugs Market by Distribution Channel
10.3 Europe
10.3.1 Eastern Europe
10.3.1.1 Eastern Europe HIV Drugs Market by Country
10.3.1.2 Eastern Europe HIV Drugs Market by Drug class
10.3.1.3 Eastern Europe HIV Drugs Market by Distribution Channel
10.3.1.4 Poland
10.3.1.4.1 Poland HIV Drugs Market by Drug class
10.3.1.4.2 Poland HIV Drugs Market by Distribution Channel
10.3.1.5 Romania
10.3.1.5.1 Romania HIV Drugs Market by Drug class
10.3.1.5.2 Romania HIV Drugs Market by Distribution Channel
10.3.1.6 Hungary
10.3.1.6.1 Hungary HIV Drugs Market by Drug class
10.3.1.6.2 Hungary HIV Drugs Market by Distribution Channel
10.3.1.7 Turkey
10.3.1.7.1 Turkey HIV Drugs Market by Drug class
10.3.1.7.2 Turkey HIV Drugs Market by Distribution Channel
10.3.1.8 Rest of Eastern Europe
10.3.1.8.1 Rest of Eastern Europe HIV Drugs Market by Drug class
10.3.1.8.2 Rest of Eastern Europe HIV Drugs Market by Distribution Channel
10.3.2 Western Europe
10.3.2.1 Western Europe HIV Drugs Market by Country
10.3.2.2 Western Europe HIV Drugs Market by Drug class
10.3.2.3 Western Europe HIV Drugs Market by Distribution Channel
10.3.2.4 Germany
10.3.2.4.1 Germany HIV Drugs Market by Drug class
10.3.2.4.2 Germany HIV Drugs Market by Distribution Channel
10.3.2.5 France
10.3.2.5.1 France HIV Drugs Market by Drug class
10.3.2.5.2 France HIV Drugs Market by Distribution Channel
10.3.2.6 UK
10.3.2.6.1 UK HIV Drugs Market by Drug class
10.3.2.6.2 UK HIV Drugs Market by Distribution Channel
10.3.2.7 Italy
10.3.2.7.1 Italy HIV Drugs Market by Drug class
10.3.2.7.2 Italy HIV Drugs Market by Distribution Channel
10.3.2.8 Spain
10.3.2.8.1 Spain HIV Drugs Market by Drug class
10.3.2.8.2 Spain HIV Drugs Market by Distribution Channel
10.3.2.9 Netherlands
10.3.2.9.1 Netherlands HIV Drugs Market by Drug class
10.3.2.9.2 Netherlands HIV Drugs Market by Distribution Channel
10.3.2.10 Switzerland
10.3.2.10.1 Switzerland HIV Drugs Market by Drug class
10.3.2.10.2 Switzerland HIV Drugs Market by Distribution Channel
10.3.2.11 Austria
10.3.2.11.1 Austria HIV Drugs Market by Drug class
10.3.2.11.2 Austria HIV Drugs Market by Distribution Channel
10.3.2.12 Rest of Western Europe
10.3.2.12.1 Rest of Western Europe HIV Drugs Market by Drug class
10.3.2.12.2 Rest of Western Europe HIV Drugs Market by Distribution Channel
10.4 Asia-Pacific
10.4.1 Asia Pacific HIV Drugs Market by Country
10.4.2 Asia Pacific HIV Drugs Market by Drug class
10.4.3 Asia Pacific HIV Drugs Market by Distribution Channel
10.4.4 China
10.4.4.1 China HIV Drugs Market by Drug class
10.4.4.2 China HIV Drugs Market by Distribution Channel
10.4.5 India
10.4.5.1 India HIV Drugs Market by Drug class
10.4.5.2 India HIV Drugs Market by Distribution Channel
10.4.6 Japan
10.4.6.1 Japan HIV Drugs Market by Drug class
10.4.6.2 Japan HIV Drugs Market by Distribution Channel
10.4.7 South Korea
10.4.7.1 South Korea HIV Drugs Market by Drug class
10.4.7.2 South Korea HIV Drugs Market by Distribution Channel
10.4.8 Vietnam
10.4.8.1 Vietnam HIV Drugs Market by Drug class
10.4.8.2 Vietnam HIV Drugs Market by Distribution Channel
10.4.9 Singapore
10.4.9.1 Singapore HIV Drugs Market by Drug class
10.4.9.2 Singapore HIV Drugs Market by Distribution Channel
10.4.10 Australia
10.4.10.1 Australia HIV Drugs Market by Drug class
10.4.10.2 Australia HIV Drugs Market by Distribution Channel
10.4.11 Rest of Asia-Pacific
10.4.11.1 Rest of Asia-Pacific HIV Drugs Market by Drug class
10.4.11.2 Rest of Asia-Pacific HIV Drugs Market by Distribution Channel
10.5 Middle East & Africa
10.5.1 Middle East
10.5.1.1 Middle East HIV Drugs Market by Country
10.5.1.2 Middle East HIV Drugs Market by Drug class
10.5.1.3 Middle East HIV Drugs Market by Distribution Channel
10.5.1.4 UAE
10.5.1.4.1 UAE HIV Drugs Market by Drug class
10.5.1.4.2 UAE HIV Drugs Market by Distribution Channel
10.5.1.5 Egypt
10.5.1.5.1 Egypt HIV Drugs Market by Drug class
10.5.1.5.2 Egypt HIV Drugs Market by Distribution Channel
10.5.1.6 Saudi Arabia
10.5.1.6.1 Saudi Arabia HIV Drugs Market by Drug class
10.5.1.6.2 Saudi Arabia HIV Drugs Market by Distribution Channel
10.5.1.7 Qatar
10.5.1.7.1 Qatar HIV Drugs Market by Drug class
10.5.1.7.2 Qatar HIV Drugs Market by Distribution Channel
10.5.1.8 Rest of Middle East
10.5.1.8.1 Rest of Middle East HIV Drugs Market by Drug class
10.5.1.8.2 Rest of Middle East HIV Drugs Market by Distribution Channel
10.5.2 Africa
10.5.2.1 Africa HIV Drugs Market by Country
10.5.2.2 Africa HIV Drugs Market by Drug class
10.5.2.3 Africa HIV Drugs Market by Distribution Channel
10.5.2.4 Nigeria
10.5.2.4.1 Nigeria HIV Drugs Market by Drug class
10.5.2.4.2 Nigeria HIV Drugs Market by Distribution Channel
10.5.2.5 South Africa
10.5.2.5.1 South Africa HIV Drugs Market by Drug class
10.5.2.5.2 South Africa HIV Drugs Market by Distribution Channel
10.5.2.6 Rest of Africa
10.5.2.6.1 Rest of Africa HIV Drugs Market by Drug class
10.5.2.6.2 Rest of Africa HIV Drugs Market by Distribution Channel
10.6 Latin America
10.6.1 Latin America HIV Drugs Market by Country
10.6.2 Latin America HIV Drugs Market by Drug class
10.6.3 Latin America HIV Drugs Market by Distribution Channel
10.6.4 Brazil
10.6.4.1 Brazil HIV Drugs Market by Drug class
10.6.4.2 Brazil HIV Drugs Market by Distribution Channel
10.6.5 Argentina
10.6.5.1 Argentina HIV Drugs Market by Drug class
10.6.5.2 Argentina HIV Drugs Market by Distribution Channel
10.6.6 Colombia
10.6.6.1 Colombia HIV Drugs Market by Drug class
10.6.6.2 Colombia HIV Drugs Market by Distribution Channel
10.6.7 Rest of Latin America
10.6.7.1 Rest of Latin America HIV Drugs Market by Drug class
10.6.7.2 Rest of Latin America HIV Drugs Market by Distribution Channel
11 Company Profile
11.1 ViiV Healthcare
11.1.1 Company Overview
11.1.2 Financials
11.1.3 Product/Services Offered
11.1.4 SWOT Analysis
11.1.5 The SNS View
11.2 Gilead Sciences
11.2.1 Company Overview
11.2.2 Financials
11.2.3 Product/Services Offered
11.2.4 SWOT Analysis
11.2.5 The SNS View
11.3 GlaxoSmithKline
11.3.1 Company Overview
11.3.2 Financials
11.3.3 Product/Services Offered
11.3.4 SWOT Analysis
11.3.5 The SNS View
11.4 Merck Sharp & Dohme Corp
11.4 Company Overview
11.4.2 Financials
11.4.3 Product/Services Offered
11.4.4 SWOT Analysis
11.4.5 The SNS View
11.5 Bristol -Myers Squibb Co
11.5.1 Company Overview
11.5.2 Financials
11.5.3 Product/Services Offered
11.5.4 SWOT Analysis
11.5.5 The SNS View
11.6 Janssen Pharmaceuticals
11.6.1 Company Overview
11.6.2 Financials
11.6.3 Product/Services Offered
11.6.4 SWOT Analysis
11.6.5 The SNS View
11.7 Boehringer Ingelheim International
11.7.1 Company Overview
11.7.2 Financials
11.7.3 Product/Services Offered
11.7.4 SWOT Analysis
11.7.5 The SNS View
11.8 Abbvie
11.8.1 Company Overview
11.8.2 Financials
11.8.3 Product/Services Offered
11.8.4 SWOT Analysis
11.8.5 The SNS View
11.9 Genentech
11.9.1 Company Overview
11.9.2 Financials
11.9.3 Product/ Services Offered
11.9.4 SWOT Analysis
11.9.5 The SNS View
11.10 Mylan
11.10.1 Company Overview
11.10.2 Financials
11.10.3 Product/Services Offered
11.10.4 SWOT Analysis
11.10.5 The SNS View
12. Competitive Landscape
12.1 Competitive Bench marking
12.2 Market Share Analysis
12.3 Recent Developments
12.3.1 Industry News
12.3.2 Company News
12.3.3 Mergers & Acquisitions
13. USE Cases and Best Practices
14. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Medical Collagen Market Size was valued at USD 6.71 billion in 2022, and is expected to reach USD 11.02 billion by 2030, and grow at a CAGR of 6.4% over the forecast period 2023-2030.
The Inflammatory Bowel Disease Drugs Market size was valued at USD 21.15 Billion in 2023 and is expected to reach USD 27.65 Billion By 2031 and grow at a CAGR of 3.47% over the forecast period of 2024-2031.
The Blood Glucose Monitoring Device Market Size was valued at USD 13.53 billion in 2023, and is expected to reach USD 24.94 billion by 2031, and grow at a CAGR of 7.94% over the forecast period 2024-2031.
The Medication Management Market Size was valued at USD 2.44 billion in 2022 and is expected to reach USD 5.62 billion by 2030, and grow at a CAGR of 11% over the forecast period 2023-2030.
The Image-guided Biopsy Market size was valued at USD 2266.21 million in 2022 and is expected to grow to USD 3386.68 million by 2030 and grow at a CAGR of 5.15% over the forecast period of 2023-2030.
The Non-Invasive Prenatal Testing (NIPT) Market is expected to reach USD 7.90 Bn by 2030 and was valued at USD 3.65 Bn in 2022, and grow at a CAGR of 10.15% over the forecast period of 2023-2030.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
